Loading…
Acute and subacute antidiabetic studies of ENP‐9, a new 1,5‐diarylpyrazole derivative
Objectives To explore the antihyperglycaemic and antidiabetic effects and to determine the acute toxicity of 5‐(4‐chlorophenyl)‐1‐(2,4‐dichloro‐phenyl)‐4‐methyl‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide (ENP‐9). Methods The antihyperglycaemic effect of ENP‐9 (50 mg/kg) was determined by oral gluc...
Saved in:
Published in: | Journal of pharmacy and pharmacology 2018-08, Vol.70 (8), p.1031-1039 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Objectives
To explore the antihyperglycaemic and antidiabetic effects and to determine the acute toxicity of 5‐(4‐chlorophenyl)‐1‐(2,4‐dichloro‐phenyl)‐4‐methyl‐N‐(piperidin‐1‐yl)‐1H‐pyrazole‐3‐carboxamide (ENP‐9).
Methods
The antihyperglycaemic effect of ENP‐9 (50 mg/kg) was determined by oral glucose tolerance test (OGTT). Also, the acute (16, 50 and 160 mg/kg) and subacute (50 mg/kg/day for 10 days) antidiabetic effects of ENP‐9 were determined. After subacute treatment, blood samples were analysed to determine glucose and lipid profiles. Also, an acute toxicity determination of ENP‐9 was conducted followed the OECD recommendation. Molecular docking was performed using AutoDock 4.2.6 at human cannabinoid receptor 1 (PDB code 5TGZ).
Key findings
Acute Administration of ENP‐9 showed significant antidiabetic effect and decreased the maximum OGTT peak, compared to the control group (P |
---|---|
ISSN: | 0022-3573 2042-7158 |
DOI: | 10.1111/jphp.12933 |